WASHINGTON — Like drug industry CEOs before them, drug middlemen are headed for the congressional hot seat.

Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), who lead the Senate Finance Committee, have invited five major pharmacy benefit managers, Cigna (CI), CVS (CVS), Humana (HUM), OptumRx and Prime Therapeutics, to testify before Congress on April 3, the pair announced Tuesday afternoon.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Well it’s about time !!! I just hope they know the right questions to ask the PBM’s. Like about Drug rebates really being a payoff to be on formulary. How about the PBM’s stealing the Price spread between AWP and what they pay the pharmacy. Why is there no transparency in their payment system? How is it that audits of 10 states medicaid systems uncovered billions of dollars stolen by the PBM’s. Why would the PBM’s bill medicare part D patients at AWP ? This puts them in the donut hole so much faster ! Why do PBM’s have a take it or leave it contract with Independent pharmacies but no one has any idea if there is any contract with their own pharmacies.
    Is it not a conflict of interest that the PBM’s decide how much they pay independent pharmacies and how much they pay themselves . Gee this sounds so much like Anti-trust to me !!!!!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy